Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Clinical Therapeutics|February 20, 2022
Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid ArthritisJong Bong Lee, Aaron Broadwell, Yijun Fan, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 17, 2025
Nipocalimab Dose Selection in Generalized Myasthenia GravisBelén Valenzuela, Martine Neyens, Yaowei Zhu, et al.
Arthritis Research & Therapy|March 22, 2022
Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitisM Elaine Husni, Atul Deodhar, Sergio Schwartzman, et al.
Paediatric Drugs|October 29, 2025
Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis DataHerta Crauwels, Sarah Ringold, Samantha Howard, et al.
Arthritis Care & Research|April 14, 2019
Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic ArthritisM Elaine Husni, Arthur Kavanaugh, Frederick Murphy, et al.
Clinical Pharmacology and Therapeutics|December 14, 2022
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic ReviewZhenhua Xu, Jocelyn H Leu, Yan Xu, et al.
DNA and Cell Biology|August 17, 2000
Complete genomic organization and promoter analysis of the round-spotted pufferfish JAK1, JAK2, JAK3, and TYK2 genesJ H Leu, S J Yan, T F Lee, et al.
The Journal of Rheumatology|April 1, 2026
Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE StudyJohn D Reveille, Atul Deodhar, Paul H Caldron, et al.
The Journal of Rheumatology|March 3, 2019
Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE StudyJohn D Reveille, Atul Deodhar, Paul H Caldron, et al.
The Journal of Rheumatology|December 17, 2015
Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD TrialEdward C Keystone, Mark C Genovese, Stephen Hall, et al.
Pageof 10